A provider briefing on Cabtreo availability in 2026. Learn about stocking issues, insurance barriers, alternative regimens, and tools to help patients.
As a prescriber of Cabtreo (Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1%), you've likely heard from patients struggling to fill their prescriptions. Despite being the first FDA-approved triple-combination topical acne treatment, Cabtreo faces persistent access challenges that can undermine treatment adherence and clinical outcomes.
This briefing covers the current availability landscape, the root causes behind access difficulties, cost and insurance considerations, and actionable steps your practice can take to support patients.
Understanding where we are helps contextualize the current situation:
Importantly, Cabtreo is not on the FDA's drug shortage list. Bausch Health's supply chain appears intact. The access issue is commercial and structural, not supply-driven.
The access challenges surrounding Cabtreo have practical implications for prescribers:
When patients can't easily fill a prescription, adherence suffers. Studies consistently show that prescription abandonment rates increase with each barrier patients encounter — whether that's cost, pharmacy availability, or prior authorization delays. For acne treatment, where consistency is critical to efficacy, these barriers can meaningfully impact outcomes.
Most commercial payers require prior authorization (PA) or step therapy for Cabtreo. Common step therapy requirements include documented failure of or intolerance to:
Practices should anticipate the PA requirement and build it into their workflow. Having documentation of prior treatment failures readily available accelerates the approval process.
Cabtreo is generally not covered by Medicare Part D. For Medicare patients with acne (less common but not rare in older adults), alternative regimens or the Bausch Health patient assistance program may be the primary options.
The access gap is driven by several converging factors:
At a wholesale acquisition cost that translates to a retail price of $960–$1,330 per pump, Cabtreo represents significant inventory risk for pharmacies. Chain pharmacies in particular use demand-based algorithms to determine stocking decisions — and newer, high-cost specialty products often fall below stocking thresholds until prescription volume grows.
Without a generic alternative, there is only one NDC to stock. This limits pharmacy purchasing flexibility and eliminates the cost competition that typically improves availability. As of 2026, no ANDA (Abbreviated New Drug Application) for a generic Cabtreo has been approved.
Cabtreo is distributed through standard pharmaceutical wholesalers (not limited distribution). However, some pharmacies may not have established ordering relationships for newer Bausch Health dermatology products, creating unnecessary delays.
Understanding the cost landscape helps you guide patient conversations:
The Rx Access Program is a meaningful tool for insured patients. Enrollment can be initiated by the prescriber's office or by the patient directly at the manufacturer's website.
Several tools can help streamline Cabtreo access for your patients:
Medfinder offers real-time pharmacy inventory data, allowing your staff to identify which pharmacies near the patient's location currently have Cabtreo in stock. This can be checked at the point of prescribing and communicated to patients before they leave the office.
When possible, e-prescribe directly to a pharmacy confirmed to have Cabtreo in stock. This avoids the patient experience of arriving at a pharmacy only to learn the medication isn't available.
Develop a standard PA letter template for Cabtreo that includes:
Train your front-office or clinical staff to proactively enroll patients in the Cabtreo Rx Access Program at the time of prescribing. This reduces sticker shock and improves fill rates.
When patients cannot access Cabtreo, the following evidence-based alternatives provide similar mechanistic coverage:
For a patient-facing comparison, direct patients to our article on alternatives to Cabtreo.
Several developments may improve Cabtreo access over time:
Cabtreo represents a genuine clinical advance — a simplified, evidence-based triple-combination regimen in a single pump. The access challenges are real but manageable with proactive practice-level strategies. By using tools like Medfinder, streamlining prior authorization workflows, enrolling patients in savings programs, and having alternative regimens ready, you can help ensure your patients get effective acne treatment without unnecessary delays.
For more provider resources, see our guide on how to help your patients find Cabtreo in stock and our article on helping patients save money on Cabtreo.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
